Cardiovascular Sympathomimetic Amine Interactions in Rats Treated with Monoamine Oxidase Inhibitors and the Novel Oxazolidinone Antibiotic Linezolid

@article{Humphrey2001CardiovascularSA,
  title={Cardiovascular Sympathomimetic Amine Interactions in Rats Treated with Monoamine Oxidase Inhibitors and the Novel Oxazolidinone Antibiotic Linezolid},
  author={Stephen J. Humphrey and J. T. Curry and Chauncey N Turman and R. P. Stryd},
  journal={Journal of Cardiovascular Pharmacology},
  year={2001},
  volume={37},
  pages={548-563}
}
Linezolid (PNU-100766) is a new gram-positive oxazolidinone antibiotic that is effective at in vitro concentrations ≤4 &mgr;g/ml and in vivo doses ≤10 mg/kg. Because linezolid also competitively inhibits human monoamine oxidase-A (MAO-A; Ki = 55 &mgr;M), we monitored its effects on the cardiovascular responses to tyramine and amine cold remedies in comparison with standard MAO inhibitors. In anesthetized rats, the pressor response to 16 &mgr;g i.v. tyramine was potentiated by the MAO-A… Expand
In Vitro, In Vivo, and Clinical Studies of Tedizolid To Assess the Potential for Peripheral or Central Monoamine Oxidase Interactions
TLDR
Provocative testing in humans and animal models failed to uncover significant signals that would suggest potential for hypertensive or serotonergic adverse consequences at the therapeutic dose of tedizolid phosphate, a weak, reversible inhibitor of MAO-A andMAO-B in vitro. Expand
Ranbezolid, a novel oxazolidinone antibacterial: in vivo characterisation of monoamine oxidase inhibitory potential in conscious rats.
TLDR
Results suggest that Ranbezolid exhibits minimal cardiovascular liability associated with MAO-A inhibition, and that co-administration of Ran bezolid with tyramine in feed or with cold remedies also did not potentiate the respective pressor responses. Expand
Effect of oral linezolid on the pressor response to intravenous tyramine.
TLDR
There was a significant difference in the pressor response to i.v. tyramine between linezolid and placebo, which underlines the advantage of within-individual comparisons of treatments in order to reduce variability and provide more accurate treatment estimates. Expand
Pharmacokinetic studies of linezolid and teicoplanin in the critically ill.
TLDR
Linezolid dosage at 600 mg every 12 h was adequate in the critically ill without need for adjustment for renal function and further study is needed to confirm if a trough of 10 mg/L is associated with a higher rate of cure than 5mg/L and if so, serum drug assays would be needed to ensure a therapeutic level. Expand
Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment
TLDR
Severe symptoms associated with serotonin toxicity were shown to be uncommon in patients receiving linezolid and selected serotonin reuptake inhibitors, and concurrent use of these medications is categorized as contraindicated. Expand
The oxazolidinones: past, present, and future
TLDR
The oxazolidinones share a relatively low frequency of resistance largely due to the requirement of mutations in 23S ribosomal RNA genes, however, maintaining potency against strains carrying the mobile cfr gene poses a challenge for the oxzolidinone class, as well as other 50S Ribosome inhibitors that target the peptidyl transferase center. Expand
High intake of dietary tyramine does not deteriorate glucose handling and does not cause adverse cardiovascular effects in mice
TLDR
The lack of serious adverse cardiovascular effects of prolonged tyramine supplementation in normoglycemic mice together with the somewhat insulin-like effects found on adipose cells should lead to reconsider favourably the risk/benefit ratio of the intake of this dietary amine. Expand
Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies
TLDR
The risk for transient, reversible hematologic effects from treatment with linezolid should be considered together with the clinical benefits associated with its use. Expand
7.23 – Oxazolidinone Antibiotics
TLDR
The medical need, key oxazolidinone attributes, discovery and development history, safety profile and toleration issues, mechanism of action (MOA) studies, and directions for future research into this new class of antibiotics are reviewed. Expand
Oxazolidin-2-ones: Antibacterial activity and chemistry
Since the introduction in the pharmaceutical market of linezolid, an oxazolidin-2-one based new class of antibacterial agents with a unique mechanism of action, this cyclic carbamate bought a widerExpand
...
1
2
...

References

SHOWING 1-10 OF 50 REFERENCES
Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
TLDR
The results suggest that befloxatone will show clinical antidepressant activity at low doses and will be devoid of the side effects associated with irreversible monoamine oxidase inhibitors. Expand
Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile.
TLDR
The neurochemical profile of befloxatone demonstrates that this compound is a selective, competitive, potent and reversible MAO-A inhibitor. Expand
Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects.
TLDR
The probability of "cheese reactions" during treatment with this reversible MAOI seems to be small, and delays of 8 and 30 days after the last doses of BROF and TCP, respectively, are needed for complete normalization of oral pressor responsiveness. Expand
Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
TLDR
The reversible MAO inhibitor moclobemide is active in animal models sensitive to all major drugs used in the treatment of depression, and lacks anticholinergic activity and it differs from classic MAO inhibitors by potentiating only weakly the pressor effect of p.o. tyramine. Expand
Blood pressure effects of monoamine oxidase inhibitors in response to orally administered tyramine in the rat
The reversible monoamine oxidase‐A inhibitors BW 1370U87, BW 616U76, brofaromine, and moclobemide, and the irreversible nonselective monoamine oxidase inhibitor phenelzine were compared forExpand
Clinical pharmacology of reversible monoamine oxidase-A inhibitors.
TLDR
Investigations of these drugs, exemplified by brofaromine, have shown a reduced and more rapidly reversed tyramine pressor sensitivity, and these results confirm the improved safety of brofarOMine, and other drugs in this class, when compared with classic MAOIs. Expand
Interaction of MAO inhibitors and dietary tyramine: a new experimental model in the conscious rat.
TLDR
A new model for tyramine-induced pressor effects in the rat is assessed and the predictivity of the test is improved by simulating the real clinical situations where tyramines is ingested with food and beverages containing the amine. Expand
Linezolid, a Novel Oxazolidinone Antibiotic: Assessment of Monoamine Oxidase Inhibition Using Pressor Response to Oral Tyramine
TLDR
Responses to tyramine when subjects took linezolid or moclobemide were significantly different from placebo, and both drugs significantly decreased tyramines oral clearance compared with placebo. Expand
Drug interactions with reversible monoamine oxidase-A inhibitors.
TLDR
The introduction of reversible inhibitors of monoamine oxidase-A (RIMAs) has greatly reduced both the number and severity of interactions and, in particular, the risk of hypertensive crises following the ingestion of tyramine (the "cheese effect"). Expand
Effect of Moclobemide, a New Reversible Monoamine Oxidase Inhibitor, on Absorption and Pressor Effect of Tyramine
TLDR
It is concluded that at doses of 3 × 100 mg/day moclobemide induces only a mild potentiation of the pressor effect of tyramine, which is virtually absent under natural conditions when tyramines is given with a meal. Expand
...
1
2
3
4
5
...